These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. Rampling T; Ewer KJ; Bowyer G; Bliss CM; Edwards NJ; Wright D; Payne RO; Venkatraman N; de Barra E; Snudden CM; Poulton ID; de Graaf H; Sukhtankar P; Roberts R; Ivinson K; Weltzin R; Rajkumar BY; Wille-Reece U; Lee CK; Ockenhouse CF; Sinden RE; Gerry S; Lawrie AM; Vekemans J; Morelle D; Lievens M; Ballou RW; Cooke GS; Faust SN; Gilbert S; Hill AV J Infect Dis; 2016 Sep; 214(5):772-81. PubMed ID: 27307573 [TBL] [Abstract][Full Text] [Related]
14. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Dunachie SJ; Walther M; Epstein JE; Keating S; Berthoud T; Andrews L; Andersen RF; Bejon P; Goonetilleke N; Poulton I; Webster DP; Butcher G; Watkins K; Sinden RE; Levine GL; Richie TL; Schneider J; Kaslow D; Gilbert SC; Carucci DJ; Hill AV Infect Immun; 2006 Oct; 74(10):5933-42. PubMed ID: 16988273 [TBL] [Abstract][Full Text] [Related]
15. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Sheehy SH; Duncan CJ; Elias SC; Collins KA; Ewer KJ; Spencer AJ; Williams AR; Halstead FD; Moretz SE; Miura K; Epp C; Dicks MD; Poulton ID; Lawrie AM; Berrie E; Moyle S; Long CA; Colloca S; Cortese R; Gilbert SC; Nicosia A; Hill AV; Draper SJ Mol Ther; 2011 Dec; 19(12):2269-76. PubMed ID: 21862998 [TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial. Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O; Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345 [TBL] [Abstract][Full Text] [Related]
17. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. Biswas S; Choudhary P; Elias SC; Miura K; Milne KH; de Cassan SC; Collins KA; Halstead FD; Bliss CM; Ewer KJ; Osier FH; Hodgson SH; Duncan CJ; O'Hara GA; Long CA; Hill AV; Draper SJ PLoS One; 2014; 9(9):e107903. PubMed ID: 25254500 [TBL] [Abstract][Full Text] [Related]
18. Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial. de Graaf H; Payne RO; Taylor I; Miura K; Long CA; Elias SC; Zaric M; Minassian AM; Silk SE; Li L; Poulton ID; Baker M; Draper SJ; Gbesemete D; Brendish NJ; Martins F; Marini A; Mekhaiel D; Edwards NJ; Roberts R; Vekemans J; Moyle S; Faust SN; Berrie E; Lawrie AM; Hill F; Hill AVS; Biswas S Front Immunol; 2021; 12():694759. PubMed ID: 34335606 [TBL] [Abstract][Full Text] [Related]